Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 12, 2008

Intertek Enhances Outsourced R&D Services through Purchase of BioClin

  • Intertek has taken over BioClin Research Laboratories. The acquisition advances Intertek’s strategic growth in support services to the global pharmaceutical, medical device, and drug delivery industry.

    BioClin will operate in Intertek’s pharmaceutical services group within its analytical services division. Originally based in Ireland, the company has been a supplier of contract bio-analysis and analytical R&D with advanced analytical services including LC/MS/MS for five years. BioClin has a GLP-certified and a cGMP facility.

    “BioClin further extends our offering in Europe as well as our global platform supporting pharmaceutical R&D and manufacturing in key locations,” notes John Conti-Ramsden, Ph.D., global director of Intertek’s pharmaceutical services. “Intertek already provides a wide range of testing services to pharmaceutical clients from its laboratories in the United Kingdom, USA, India, and Australia.”



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »